Head to Head Survey: TC Biopharm (NASDAQ:TCBP) and Halozyme Therapeutics (NASDAQ:HALO)

TC Biopharm (NASDAQ:TCBP) and Halozyme Therapeutics (NASDAQ:HALO) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, earnings, dividends, profitability and risk.

Profitability

This table compares TC Biopharm and Halozyme Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TC Biopharm	N/A	N/A	N/A
Halozyme Therapeutics	41.43%	179.82%	23.56%

Institutional & Insider Ownership

16.3% of TC Biopharm shares are held by institutional investors. Comparatively, 97.8% of Halozyme Therapeutics shares are held by institutional investors. 15.4% of TC Biopharm shares are held by insiders. Comparatively, 2.4% of Halozyme Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares TC Biopharm and Halozyme Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TC Biopharm	$4.76 million	0.08	-$7.35 million	N/A	N/A
Halozyme Therapeutics	$947.36 million	6.46	$281.59 million	$3.02	15.94

Halozyme Therapeutics has higher revenue and earnings than TC Biopharm.

Risk & Volatility

TC Biopharm has a beta of 0.02, suggesting that its share price is 98% less volatile than the S&P 500. Comparatively, Halozyme Therapeutics has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations and price targets for TC Biopharm and Halozyme Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TC Biopharm	0	0	1	0	3.00
Halozyme Therapeutics	0	4	6	0	2.60

TC Biopharm presently has a consensus target price of $3.00, suggesting a potential upside of 322.54%. Halozyme Therapeutics has a consensus target price of $61.11, suggesting a potential upside of 26.97%. Given TC Biopharm’s stronger consensus rating and higher possible upside, equities analysts plainly believe TC Biopharm is more favorable than Halozyme Therapeutics.

Summary

Halozyme Therapeutics beats TC Biopharm on 9 of the 12 factors compared between the two stocks.

About TC Biopharm

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.